Kesios Therapeutics Ltd.
Targeting the NF-κB pathway in cancer drug discovery
This article was originally published in Start Up
Executive Summary
The NF-κB pathway plays a key role in inflammation and immunity, but it is increasingly understood to be important in cancer. Kesios Therapeutics Ltd. and Imperial College London are working in parallel to develop therapeutics targeting the pathway for the treatment of cancer, and move them into clinical trials.